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O-Sulfated sialyl Lewis x antigens play important roles in nature. However, due to their structural
complexity, they are not readily accessible by either chemical or enzymatic synthetic processes. Taking
advantage of a bacterial sialyltransferase mutant that can catalyze the transfer of different sialic acid
forms from the corresponding sugar nucleotide donors to Lewis x antigens, which are fucosylated
glycans, as well as an efficient one-pot multienzyme (OPME) sialylation system, O-sulfated sialyl Lewis x
antigens containing different sialic acid forms and O-sulfation at different locations were systematically
synthesized by chemoenzymatic methods.Introduction
O-Sulfated sialyl Lewis x structures play important roles in
immune regulation, inammation, and cancer metastasis.1 For
example, 6-O-sulfo-sialyl Lewis x [6-O-sulfo-sLex (1), Neu5Aca2-
3Galb1-4(Fuca1-3)GlcNAc6SbOR] with an O-sulfate group at the
carbon-6 of the N-acetylglucosamine (GlcNAc) residue (Fig. 1) is
a well known ligand for L-selectin, a C-type (Ca2+-dependent)
carbohydrate-binding protein (lectin) expressed broadly inmost
leukocytes in the blood.1,2 The interaction of 6-O-sulfo-sLex (1)
and L-selectin plays a critical role in lymphocyte homing to the
peripheral lymph nodes2 and in chronic inammation.3 It has
also been shown that human sialic acid-binding immunoglob-
ulin-like lectin4 Siglec-9 binds strongly5,6 to 6-O-sulfo-sLex, but
the biological importance of this interaction is less well
understood.
On the other hand, 60-O-sulfo-sialyl Lewis x [60-O-sulfo-sLex
(2), Neu5Aca2-3Gal6Sb1-4(Fuca1-3)GlcNAcbOR] with an O-
sulfate group at the carbon-6 of the galactose (Gal) residue
(Fig. 1),7 in addition to 60-O-sulfo-sialyl-N-acetyllactosamine (60-
O-sulfo-sLacNAc, Neu5Aca2-3Gal6Sb1-4GlcNAcbOR),8 wasifornia, Davis One Shields Avenue, Davis,
u; Fax: +1-530-752-8995; Tel: +1-530-754-
cience and Technology, Xinxiang, 453003,
Sleep Medicine, Department of Internal
A 95616, USA
iversity of California, Davis, CA 95616,
(ESI) available: Materials, experimental
of 4–10, 1a–3a, and 1b–3b, and NMR
OI: 10.1039/c5sc04104j
edical Center, Washington DC, 20010,
hemistry 2016shown by glycan microarray studies to be a preferred glycan
ligand for Siglec-8 and for its paralog mouse Siglec-F.9 Siglec-8 is
expressed in human allergic inammatory cells including
eosinophils, mast cells, and basophils.5,10 Reducing the number
of eosinophils, such as by soluble 60-O-sulfo-sLex synthetic
polymer induced apoptosis,11 has been suggested as an
approach for asthma therapies.12 Furthermore, 60-O-sulfo-sLex
(2), in addition to 60-O-sulfo-sLacNAc and 60-O-sulfo-sialyl-lacto-
N-neotetraose (60-O-sulfo-sLNnT, Neu5Aca2-3Gal6Sb1-
4GlcNAcb1-3Galb1-4GlcbOR), was shown to bind to langerin,13
a C-type (Ca2+-dependent) lectin specic to Langerhans cells
(immature antigen-presenting specic T cell immunity initi-
ating dendritic cells of epidermis and mucosal tissues).14
Although less efficient than Neu5Aca2-8Neu5Aca2-3LacNAc,
both 6-O-sulfo-sLex (1) and 60-O-sulfo-sLex (2) bound moderatelyFig. 1 Structures ofO-sulfated sialyl Lewis x including 6-O-sulfo-sLex
(1), 60-O-sulfo-sLex (2), and 60, 6-di-O-sulfo-sLex (3).
Chem. Sci., 2016, 7, 2827–2831 | 2827
Fig. 2 Structures of chemically synthesized 60-O-sulfo-
LacNAcbProN3 (5) and 6,60-di-O-sulfo-LacNAcbProN3 (6).
Chemical Science Edge Article
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View Article Onlineto human Siglec-7.5 Both are present in glycosylation-dependent
cell adhesion molecule 1 (GlyCAM-1), an L-selectin ligand,15
with 60-O-sulfo-sLex (2) as the major sulfated form.16–18 Gal-6-O-
sulfotransferase and GlcNAc-6-O-sulfotransferase have been
found to synergistically produce L-selectin ligands. This indi-
cates either the potential synergistic involvement of both 6-O-
sulfo-sLex (1) and 60-O-sulfo-sLex (2) or the involvement of 60,6-
di-O-sulfo-sLex (3) (Fig. 1) with O-sulfate groups at both the Gal
and GlcNAc residues of sLex in L-selectin-binding.19 Human
Siglec-7 and -8 have also been shown to bind more strongly to
60,6-di-O-sulfo-sLex (3) than their mono-O-sulfated derivatives (1
and 2), while mouse Siglec-F has been shown to bind with
similar strength to 60,6-di-O-sulfo-sLex (3) and 60-O-sulfo-sLex
(2).6
The biological importance of O-sulfated sLex structures
makes them attractive synthetic targets. However, the structures
of these compounds are relatively complex and include
synthetically challenging a2-3-linked sialic acid, which suffers
from low stereoselectivity and a high 2,3-elimination rate in
chemical synthesis,20–22 as well as the acid labile O-sulfate
group.23,24 Chemically20,25,26 or chemoenzymatically27 synthe-
sized Neu5Aca2-3Gal building blocks have been used as effec-
tive synthons for constructing more complex sialosides
including sLex and 6-O-sulfo-sLex (1).20 Several examples of the
chemical22,28 or chemoenzymatic29 synthesis of 6-O-sulfo-sLex
(1) as well as the chemical synthesis of 60-O-sulfo-sLex (2)22,30,31
and 60,6-di-O-sulfo-sLex (3)32 have been reported. All these
examples are, however, limited to compounds with the most
abundant sialic acid form, N-acetylneuraminic acid (Neu5Ac).
Despite the presence of more than 50 different sialic acid formsScheme 1 Sequential OPME synthesis of 6-O-sulfo-LexbProN3 (8)
from 6-O-sulfo-GlcNAcbProN3 (7) using an OPME b1-4-galactosyl
activation and transfer system for the formation of 6-O-sulfo-
LacNAcbProN3 (4) followed by an OPME a1-3-fucosyl activation and
transfer system for the formation of 6-O-sulfo-LexbProN3 (8).
Enzymes and abbreviations: SpGalK, Streptococcus pneumoniae
TIGR4 galactokinase;44 BLUSP, Bifidobacterium longum UDP-sugar
pyrophosphorylase;45 PmPpA, Pasteurella multocida inorganic pyro-
phosphorylase;43 Hp4GalT, Helicobacter pylori b1-4-galactosyl-
transferase;43 BfFKP, Bacteroides fragilis bifunctional L-fucokinase/
GDP-fucose pyrophosphorylase;42 and Hp3FT, Helicobacter pylori a1-
3-fucosyltransferase.39,41
2828 | Chem. Sci., 2016, 7, 2827–2831identied in nature,33,34 O-sulfated sLex containing a sialic acid
form other than Neu5Ac has not been synthesized.
We report here the development of efficient chemoenzymatic
methods for the systematic synthesis of O-sulfated sLex con-
taining different sialic acid forms. The methods are demon-
strated for representative examples of 60-O-sulfo-sLex (1), 6-O-
sulfo-sLex (2) and/or 60,6-di-O-sulfo-sLex (3) containing the most
abundant Neu5Ac form and N-glycolylneuraminic acid
(Neu5Gc), a sialic acid form commonly found in mammals
other than humans, but which can be incorporated into the
human glycome from dietary sources.35
One efficient approach for the synthesis of O-sulfated sLex
with different sialic acid forms would be by direct sialylation of
O-sulfated Lex using one-pot multienzyme (OPME) sialylation
systems36 containing an a2-3-sialyltransferase and a CMP-sialic
acid synthetase (CSS),37 with or without a sialic acid aldolase.38
Such an approach has been successfully demonstrated for
direct sialylation of non-sulfated Lex for the synthesis of sLex
containing a diverse array of naturally occurring and non-
natural sialic acid forms, using OPME systems containing
a recombinant viral a2-3-sialyltransferase vST3Gal-I39 or
a bacterial multifunctional sialyltransferase mutant, PasteurellaScheme 2 Chemical synthesis of 60-O-sulfo-LexbProNH2 (9) and
6,60-di-O-sulfo-LexbProNH2 (10). Reagents and conditions: (a) N-
iodosuccinimide (NIS), TMSOTf, MS 4 A˚, CH2Cl2, 40 C, 30 min; (b)
N-iodosuccinimide (NIS), TMSOTf, MS 4 A˚, CH2Cl2–Et2O (1 : 1), 18
C, 45 min; (c) H2N(CH2)2NH2, n-BuOH, 90 C, 8 h; (d) pyridine, Ac2O,
r.t., 10 h; (e) HF pyridine, 0 C to r.t., overnight; (f) SO3 pyridine, pyri-
dine, 0 C to r.t.; (g) 0.1 M NaOMe, MeOH, r.t., 3 h; (h) Pd(OH)2/C, H2,
CH3OH, 48 h.
This journal is © The Royal Society of Chemistry 2016
Scheme 3 PmST1 M144D-mediated one-pot two-enzyme (OP2E)
sialylation of O-sulfo analogues of Lewisx. Yields obtained for O-
sulfated sLex tetrasaccharides: 1a, 85%; 1b, 47%; 2a, 82%; 2b, 60%; 3a,
64%; 3b, 38%. Enzymes and abbreviations: NmCSS, Neisseria menin-
gitidis CMP-sialic acid;37 PmST1 M144D, Pasteurella multocida a2-3-
sialyltransferase 1 (PmST1) M144D mutant.40
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View Article Onlinemultocida a2-3-sialyltransferase 1 (PmST1) M144D.40 The latter,
with a high expression level (98 mg L-1 culture, >1000-fold
higher than that of vST3Gal-I) and high promiscuity in toler-
ating different modications on the sialic acid in the substrates,
is a superior choice for the synthesis.40 However, it is not clear
whether O-sulfated Lex structures could be used with PmST1
M144D as suitable acceptors in the OPME sialylation process to
produce the desired O-sulfated sLex with different sialic acid
forms.Results and discussion
Synthesis of O-sulfated disaccharides and O-sulfated Lex
In order to obtain O-sulfated Lex as potential acceptor
substrates for PmST1 M144D, enzyme-catalyzed a1-3-fucosyla-
tion of the corresponding O-sulfated disaccharides was tested
as a potential strategy. A one-pot three-enzyme (OP3E) a1-3-
fucosylation system (Scheme 1)39,41 containing Bacteroides fra-
gilis bifunctional L-fucokinase/GDP-fucose pyrophosphorylase
(BfFKP),42 Pasteurella multocida inorganic pyrophosphorylase
(PmPpA),43 and Helicobacter pylori a1-3-fucosyltransferase (Hp1-
3FTD66 or Hp3FT) was used for this purpose. The O-sulfated
disaccharides tested were 6-O-sulfo-LacNAcbProN3 (4) (Scheme
1), 60-O-sulfo-LacNAcbProN3 (5), and 6,60-di-O-sulfo-
LacNAcbProN3 (6) (Fig. 2). LacNAcbProN3 (ref. 43) without any
O-sulfate groups was used as a positive control.
6-O-Sulfo-LacNAcbProN3 (4) was synthesized from 6-O-sulfo-
GlcNAcbProN3 (7)43 using an improved OPME galactosyl acti-
vation and transfer system (Scheme 1) containing Streptococcus
pneumoniae TIGR4 galactokinase (SpGalK),44 Bidobacterium
longum UDP-sugar pyrophosphorylase (BLUSP),45 PmPpA, and
a Helicobacter pylori b1-4-galactosyltransferase (Hp1-4GalT or
Hp4GalT).43 The EcGalK, BLUSP, and PmPpA allowed in situ
formation of the donor substrate of Hp4GalT, uridine 50-
diphosphate-galactose (UDP-Gal), from monosaccharideThis journal is © The Royal Society of Chemistry 2016galactose (Gal).45 It was previously shown that Hp4GalT, but not
Neisseria meningitidis b1-4-galactosyltransferase (NmLgtB), was
able to use 6-O-sulfated GlcNAc and derivatives as acceptor
substrates for the synthesis of b1-4-linked galactosides.43 The
activity of Hp4GalT in synthesizing 6-O-sulfo-LacNAcbProN3 (4)
was conrmed again here using the improved OPME
approach.45,46 An excellent 89% yield was obtained, comparing
favourably to the previous Hp4GalT-dependent OPME b1-4-
galactosylation approach (70% yield) which used Escherichia coli
K-12 glucose-1-P uridylyltransferase (EcGalU), Escherichia coli
UDP-galactose-4-epimerase (EcGalE), and PmPpA to produce
UDP-Gal in situ from glucose-1-phosphate.43 60-O-Sulfo-
LacNAcbProN3 (5) and 6,60-di-O-sulfo-LacNAcbProN3 (6) (Fig. 2)
were chemically synthesized (see ESI†).
Among the three O-sulfated disaccharides tested, only 6-O-
sulfo-LacNAcbProN3 (4) was a suitable acceptor for Hp3FT to
produce the desired 6-O-sulfo-LexbProN3 (8). In contrast, 60-O-
sulfo-LacNAcbProN3 (5) and 6,60-di-O-sulfo-LacNAcbProN3 (6)
were not used efficiently by Hp3FT for the synthesis of the
corresponding O-sulfated Lex derivatives. With the positive
outcome in small scale reactions for fucosylation of 6-O-sulfo-
LacNAcbProN3 (4), the preparative-scale synthesis of 6-O-sulfo-
LexbProN3 (8) was carried out using the OP3E a1-3-fucosyl
activation and transfer system (Scheme 1). A yield of 70% was
obtained. The combined sequential OPME b1-4-galactosylation
and OPME a1-3-fucosylation (Scheme 1) was an effective
approach for obtaining 6-O-sulfo-LexbProN3 (8) from a simple
monosaccharide derivative 6-O-sulfo-GlcNAcbProN3 (7) in an
overall yield of 62%.
As Hp3FT was not able to use 60-O-sulfo-LacNAcbProN3 (5) or
6,60-di-O-sulfo-LacNAcbProN3 (6) efficiently as acceptors for
fucosylation to obtain the desired Lex trisaccharides, the target
trisaccharides 60-O-sulfo-LexbProNH2 (9) and 6,60-di-O-sulfo-
LexbProNH2 (10) were chemically synthesized (Scheme 2) from
monosaccharide synthons 11, 12,27 13, and 14.27 Notable
features of the synthetic strategy include: (a) application of an
efficient general protection strategy47 for the synthesis of the
two trisaccharides (i.e. similar protecting groups were used in
the syntheses and the same reagents were used for their
removal); (b) use of similar thioglycoside derivatives as glycosyl
donors in all glycosylations; (c) high regio- and stereoselectivity
in product formation; (d) one step removal of benzyl ethers and
reduction of the azido group using 20% Pd(OH)2/C (Pearlman's
catalyst) and H2.48 More specically, for the synthesis of 9 and
10, two N-phthalimide glucosamine derivatives 11 and 12
selectively protected at C6 with benzyl and tert-butyldiphe-
nylsilyl ether (TBDPS), respectively, were coupled stereo-
selectively with thioglycoside donor 13, which was selectively
protected with TBDPS at C6, in the presence of N-iodosuccini-
mide (NIS) and trimethylsilyl triuoromethanesulfonate
(TMSOTf)49 in dichloromethane. Disaccharide derivatives 15
and 16 were obtained in 72% and 78% yields, respectively. The
bulky N-phthalimido protecting group in acceptors 11 and 12
provides steric hindrance to the neighboring C-3 hydroxyl group
and decreases the reactivity of the C-3 hydroxyl group. There-
fore, glycosylation occurs regioselectively at the C-4 hydroxyl
group.27 Initial attempts to glycosylate acceptors 15 and 16 inChem. Sci., 2016, 7, 2827–2831 | 2829
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View Article Onlinedichloromethane with 1.2 equivalents of thiophenyl fucoside 14
produced trisaccharides in alpha and beta mixtures. In
contrast, stereospecic formation of trisaccharides was ach-
ieved when a mixed solvent of diethylether and dichloro-
methane (1 : 1)50,51 was employed. The reaction of acceptors 15
and 16 with 1.2 equivalents of fucosyl donor 14 produced
compounds 17 and 18 in 68% and 65% yields, respectively.
Compounds 17 and 18 were then subjected to a series of
synthetic transformations: (a) conversion of the N-phthaloyl
group to an acetamido group by removing the phthaloyl group
using ethylenediamine, followed by N- and O-acetylation using
acetic anhydride and pyridine; (b) HF-pyridine-mediated selec-
tive removal of the TBDPS group;52 (c) O-sulfation of the primary
hydroxyl group by SO3 pyridine complex;52,53 (d) deacetylation by
NaOMe in MeOH;54 and (e) hydrogenation using Pd(OH)2/C and
H2 (ref. 55) to obtain the desired 60-O-sulfo-Le
xbProNH2 (9) and
6,60-di-O-sulfo-LexbProNH2 (10).Enzymatic synthesis of O-sulfated sLex
With chemoenzymatically synthesized 6-O-sulfo-LexbProN3 (8)
as well as chemically synthesized 60-O-sulfo-LexbProNH2 (9) and
6,60-di-O-sulfo-LexbProNH2 (10) in hand, a one-pot two-enzyme
(OP2E) sialylation system (Scheme 3) was used to test the
tolerance of PmST1 M144D40 for using these O-sulfated Lex
compounds as potential acceptor substrates. PmST1 M144D
was previously engineered by protein crystal structure-assisted
design. It has 20-fold reduced CMP-sialic acid (donor) hydro-
lysis activity and signicantly (5588-fold) decreased a2-3-siali-
dase activity compared to the wild-type enzyme. It was used
efficiently in a one-pot three-enzyme (OP3E) sialylation system
for the synthesis of non-sulfated sLex tetrasaccharides con-
taining diverse sialic acid forms from Lex.40 To our delight,
PmST1 M144D also tolerated O-sulfated Lex containing O-
sulfate at C-6, C-60, or both. In addition to N-acetylneuraminic
acid (Neu5Ac), N-acetylneuraminic acid (Neu5Gc) was also
successfully introduced to compounds 8–10. O-Sulfated sLex
tetrasaccharides 6-O-sulfo-Neu5Aca2-3LexbProN3 (1a, 80 mg,
85%), 6-O-sulfo-Neu5Gca2-3LexbProN3 (1b, 22 mg, 47%), 60-O-
sulfo-Neu5Aca2-3LexbProNH2 (2a, 75 mg, 82%), 60-O-sulfo-
Neu5Aca2-3LexbProNH2 (2b, 45 mg, 60%), 6,60-di-O-sulfo-
Neu5Aca2-3LexbProNH2 (3a, 42 mg, 64%), and 6,60-di-O-sulfo-
Neu5Gca2-3LexbProNH2 (3b, 40 mg, 38%) were successfully
obtained using this highly efficient one-pot two-enzyme system
containingNeisseria meningitidis CMP-sialic acid (NmCSS)37 and
PmST1 M144D40 from the corresponding acceptors 8–10 and
Neu5Ac or Neu5Gc, respectively. In general, Neu5Gc was used
less efficiently by the OPME sialylation system, leading to lower
yields for 1b–3b (38–60%) compared to their Neu5Ac-counter-
parts 1a–3a (64–85%). O-Sulfated sLex glycans with a propyl
amine aglycone (compounds 2a, 3a, 2b and 3b) were found to be
more challenging for column purication compared to the ones
with a propyl azide aglycone (compounds 1a and 1b). When
a desired sialic acid is readily available such as in the case
presented here, a one-pot two-enzyme (OP2E) system is suffi-
cient. When only the 6-carbon precursors of the desired sialic
acid forms are available, the one-pot three-enzyme (OP3E)2830 | Chem. Sci., 2016, 7, 2827–2831sialylation system including an aldolase in addition to NmCSS
and PmST1 M144D40 should be used.Conclusions
In conclusion, we have successfully developed an efficient
chemoenzymatic method for the systematic synthesis of
synthetically challenging O-sulfated sLex (1a–3a and 1b–3b)
containing different sialic acid forms (Neu5Ac or Neu5Gc) by
direct sialylation of the corresponding O-sulfated Lex structures
8–10 using an efficient one-pot two-enzyme (OP2E) system
containing NmCSS and PmST1 M144D. The method can be
extended to the synthesis of O-sulfated sLex structures con-
taining other sialic acid forms. We have also shown here that
a relatively complex trisaccharide 6-O-sulfo-LexbProN3 (8) can
be efficiently produced from a simple monosaccharide deriva-
tive 6-O-sulfo-GlcNAcbProN3 (7) by a sequential OPME b1-4-
galactosylation and OPME a1-3-fucosylation process. PmST1
M144D has been demonstrated to be a powerful catalyst not
only for synthesizing non-sulfated sLex structures as shown
previously,40 but also for producing biologically important but
difficult-to-obtain O-sulfated sLex.Acknowledgements
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